Acquisitions - Narrative (Details) - USD ($) $ / shares in Units, $ in Millions			1 Months Ended			3 Months Ended
	Dec. 31, 2026	Jul. 02, 2024	Mar. 31, 2026	Jan. 31, 2026	Nov. 30, 2025	Mar. 31, 2026	Mar. 31, 2025
Business Combination [Line Items]
Payments to acquire in process research and development						$ 35.0	$ 0.0
Alcyone Therapeutics, Inc.
Business Combination [Line Items]
Payments to acquire productive assets		$ 85.0
Payments to acquire in process research and development				$ 35.0	$ 50.0
Asset acquisition, contingent consideration, range of outcomes, maximum, amount					$ 75.0
Apellis Pharmaceuticals, Inc.
Business Combination [Line Items]
Price per share (in dollars per share)			$ 41.00			$ 41.00
Business combination, consideration transferred			$ 5,600.0
Payment to shareholder (in dollars per share)			$ 4.00			$ 4.00
Apellis Pharmaceuticals, Inc. | Forecast
Business Combination [Line Items]
Cash paid for acquisition	$ 3,600.0
Bank loans used for acquisiton	$ 2,000.0